MetaCap

Benitec Biopharma (BNTC) vs ARS Pharmaceuticals (SPRY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Benitec Biopharma (BNTC) has outperformed ARS Pharmaceuticals (SPRY) over the past year, losing 40.3% versus a loss of 61.0%. Over five years, SPRY leads with a -58.8% price change compared with -85.7% for BNTC. ARS Pharmaceuticals is the larger company by market cap ($297.6 million vs $285.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BNTC-40.31%SPRY-61.00%
+79%+3%-72%
Nov 21, 20251 yearNov 20, 2026
BNTC-85.45%SPRY-63.99%
+132%+13%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BNTC versus SPRY key metrics
MetricBNTCSPRY
Share price$7.92$2.96
Market cap$285.88M$297.56M
1-day change-2.76%-11.90%
YTD return-41.24%-74.59%
1-year return-40.31%-61.00%
5-year return-85.67%-58.83%
EPS (TTM)$-1.02$-2.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$84.28M
Revenue growth (YoY)—-5.46%
Net income (latest FY)$-45.55M$-171.30M
Operating margin—-212.92%
Net margin—-203.25%
52-week high$14.39$13.15
52-week low$7.72$2.44
Distance from 52-week high-45.00%-77.49%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+200.06%+474.32%
Average volume174.01K1.83M
Shares outstanding36.12M100.53M
Employees24203
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BNTC has outperformed SPRY by 20.7 percentage points over the past year.

About Benitec Biopharma

BNTC stock →

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.

Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees

About ARS Pharmaceuticals

SPRY stock →

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.

Health Care · Biotechnology: Pharmaceutical Preparations · 203 employees

BNTC vs SPRY FAQ

Which is bigger, Benitec Biopharma or ARS Pharmaceuticals?

ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $297.56M compared with $285.88M for Benitec Biopharma (BNTC).

Which stock has performed better over the past year, BNTC or SPRY?

BNTC returned -40.31% over the past 12 months, compared with -61.00% for SPRY (price return, excluding dividends). Past performance does not predict future results.

Are Benitec Biopharma and ARS Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons